Botensilimab

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Botensilimab and Balstilimab Optimization in Colorectal Cancer

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

The Seven Trial: Exploiting the Unfolded Protein Response

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer